Regulation and function of autophagy in pancreatic cancer
Oncogenic KRAS mutation-driven pancreatic ductal adenocarcinoma is currently the fourth-
leading cause of cancer-related deaths in the United States. Macroautophagy (hereafter …
leading cause of cancer-related deaths in the United States. Macroautophagy (hereafter …
[HTML][HTML] Connections between endoplasmic reticulum stress-associated unfolded protein response, mitochondria, and autophagy in arsenic-induced carcinogenesis
P Wadgaonkar, F Chen - Seminars in cancer biology, 2021 - Elsevier
Arsenic exposure in contaminated drinking water is a global health issue, as more than 200
million people are affected globally. Arsenic has been known to cause skin, liver, lung …
million people are affected globally. Arsenic has been known to cause skin, liver, lung …
[HTML][HTML] Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
S Tang, Y Shen, X Wei, Z Shen, W Lu, J Xu - Cell Death & Disease, 2022 - nature.com
Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors are efficacious in treating platinum-
sensitive ovarian cancer (OC), but demonstrate limited efficiency in patients with platinum …
sensitive ovarian cancer (OC), but demonstrate limited efficiency in patients with platinum …
[HTML][HTML] Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and …
A Ali, J Shafarin, H Unnikannan, N Al-Jabi… - … journal of biological …, 2021 - ncbi.nlm.nih.gov
Abstract BET bromodomain BRD4 and RAC1 oncogenes are considered important
therapeutic targets for cancer and play key roles in tumorigenesis, survival and metastasis …
therapeutic targets for cancer and play key roles in tumorigenesis, survival and metastasis …
[HTML][HTML] Cytoprotective, cytotoxic and cytostatic roles of autophagy in response to BET inhibitors
AM Elshazly, DA Gewirtz - International Journal of Molecular Sciences, 2023 - mdpi.com
The bromodomain and extra-terminal domain (BET) family inhibitors are small molecules
that target the dysregulated epigenetic readers, BRD2, BRD3, BRD4 and BRDT, at various …
that target the dysregulated epigenetic readers, BRD2, BRD3, BRD4 and BRDT, at various …
[HTML][HTML] The BET inhibitor JQ1 augments the antitumor efficacy of gemcitabine in preclinical models of pancreatic cancer
AL Miller, PL Garcia, SC Fehling, TL Gamblin… - Cancers, 2021 - mdpi.com
Simple Summary The BET bromodomain inhibitor JQ1 slows tumor growth in preclinical
models of pancreatic cancer. However, as a single agent, it does not induce tumor …
models of pancreatic cancer. However, as a single agent, it does not induce tumor …
Combination treatment with cyclosporin A and arsenic trioxide induce synergistic cell death via non-apoptotic pathway in uterine cervical cancer cells
PJ Wu, IL Hsin, WL Hung, MS Lee, PH Wang… - Chemico-Biological …, 2022 - Elsevier
Cyclosporin A is an immunosuppressive drug with anti-cancer effect. Arsenic trioxide (As 2 O
3), a well-known cancer-inhibiting drug, induced cytotoxicity via apoptosis and autophagy …
3), a well-known cancer-inhibiting drug, induced cytotoxicity via apoptosis and autophagy …
[HTML][HTML] Metformin and arsenic trioxide synergize to trigger Parkin/pink1-dependent mitophagic cell death in human cervical cancer HeLa cells
J Chen, C Zhou, J Yi, J Sun, B Xie, Z Zhang… - Journal of …, 2021 - ncbi.nlm.nih.gov
Mitochondria are involved in various biological processes including intracellular
homeostasis, proliferation, senescence, and death, and mitochondrial mitophagy is closely …
homeostasis, proliferation, senescence, and death, and mitochondrial mitophagy is closely …
[HTML][HTML] Arsenic trioxide activates yes-associated protein by lysophosphatidic acid metabolism to selectively induce apoptosis of vascular smooth muscle cells
H Yu, Z Hou, M Xiang, F Yang, J Ma, L Yang… - … et Biophysica Acta (BBA …, 2022 - Elsevier
Inhibition of vascular smooth muscle cells (VSMCs) proliferation without dysregulating
endothelial cells (ECs) may provide an ideal therapy for in-stent restenosis. Due to its anti …
endothelial cells (ECs) may provide an ideal therapy for in-stent restenosis. Due to its anti …
A folic acid-decorated nanoparticles loaded JQ1 for oral squamous cell carcinoma therapy
D Zeng, Z Ma, X Zan, T Luo, X Wang, X Gao… - Chinese Chemical …, 2024 - Elsevier
Oral squamous cell carcinoma (OSCC) is known as one of the most malignant tumors with
high recurrence and fatality rate. The poor tumor-targeting ability of traditional …
high recurrence and fatality rate. The poor tumor-targeting ability of traditional …